These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 27169545)

  • 1. CCL11-induced eosinophils inhibit the formation of blood vessels and cause tumor necrosis.
    Xing Y; Tian Y; Kurosawa T; Matsui S; Touma M; Yanai T; Wu Q; Sugimoto K
    Genes Cells; 2016 Jun; 21(6):624-38. PubMed ID: 27169545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of blood vessel formation in tumors by IL-18-polarized M1 macrophages.
    Xing Y; Tian Y; Kurosawa T; Matsui S; Touma M; Wu Q; Sugimoto K
    Genes Cells; 2016 Mar; 21(3):287-95. PubMed ID: 26791003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.
    Huaux F; Gharaee-Kermani M; Liu T; Morel V; McGarry B; Ullenbruch M; Kunkel SL; Wang J; Xing Z; Phan SH
    Am J Pathol; 2005 Dec; 167(6):1485-96. PubMed ID: 16314464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance.
    Simson L; Ellyard JI; Dent LA; Matthaei KI; Rothenberg ME; Foster PS; Smyth MJ; Parish CR
    J Immunol; 2007 Apr; 178(7):4222-9. PubMed ID: 17371978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel, selective, and orally available antagonist for CC chemokine receptor 3.
    Morokata T; Suzuki K; Masunaga Y; Taguchi K; Morihira K; Sato I; Fujii M; Takizawa S; Torii Y; Yamamoto N; Kaneko M; Yamada T; Takahashi K; Shimizu Y
    J Pharmacol Exp Ther; 2006 Apr; 317(1):244-50. PubMed ID: 16339911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning and characterization of the guinea pig eosinophil eotaxin receptor, C-C chemokine receptor-3: blockade using a monoclonal antibody in vivo.
    Sabroe I; Conroy DM; Gerard NP; Li Y; Collins PD; Post TW; Jose PJ; Williams TJ; Gerard CJ; Ponath PD
    J Immunol; 1998 Dec; 161(11):6139-47. PubMed ID: 9834099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL11-CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation.
    Miyagaki T; Sugaya M; Murakami T; Asano Y; Tada Y; Kadono T; Okochi H; Tamaki K; Sato S
    Cancer Res; 2011 Mar; 71(6):2056-65. PubMed ID: 21406396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The allergy-associated chemokine receptors CCR3 and CCR5 can be inactivated by the modified chemokine NNY-CCL11.
    Manns J; Rieder S; Escher S; Eilers B; Forssmann WG; Elsner J; Forssmann U
    Allergy; 2007 Jan; 62(1):17-24. PubMed ID: 17156337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists.
    Mori A; Ogawa K; Someya K; Kunori Y; Nagakubo D; Yoshie O; Kitamura F; Hiroi T; Kaminuma O
    Int Immunol; 2007 Aug; 19(8):913-21. PubMed ID: 17804691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration.
    Kodali RB; Kim WJ; Galaria II; Miller C; Schecter AD; Lira SA; Taubman MB
    Arterioscler Thromb Vasc Biol; 2004 Jul; 24(7):1211-6. PubMed ID: 15130922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation.
    Fulkerson PC; Fischetti CA; McBride ML; Hassman LM; Hogan SP; Rothenberg ME
    Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16418-23. PubMed ID: 17060636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling.
    Fulkerson PC; Fischetti CA; Rothenberg ME
    Am J Pathol; 2006 Dec; 169(6):2117-26. PubMed ID: 17148674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eotaxin/CCL11 in idiopathic retroperitoneal fibrosis.
    Mangieri D; Corradi D; Martorana D; Malerba G; Palmisano A; Libri I; Bartoli V; Carnevali ML; Goldoni M; Govoni P; Alinovi R; Buzio C; Vaglio A
    Nephrol Dial Transplant; 2012 Oct; 27(10):3875-84. PubMed ID: 23114905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteinase-activated receptor 2 blockade impairs CCL11- or allergen-induced eosinophil recruitment in experimental pleurisy.
    Matos NA; Silva JF; Damasceno KA; Cassali GD; Lemos VS; Duarte ID; Klein A
    Eur J Pharmacol; 2014 Oct; 740():627-33. PubMed ID: 24972241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-talk between macrophage migration inhibitory factor and eotaxin in allergic eosinophil activation forms leukotriene C₄-synthesizing lipid bodies.
    Vieira-de-Abreu A; Calheiros AS; Mesquita-Santos FP; Magalhães ES; Mourão-Sá D; Castro-Faria-Neto HC; Bozza MT; Bandeira-Melo C; Bozza PT
    Am J Respir Cell Mol Biol; 2011 Apr; 44(4):509-16. PubMed ID: 20539011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.
    Heath H; Qin S; Rao P; Wu L; LaRosa G; Kassam N; Ponath PD; Mackay CR
    J Clin Invest; 1997 Jan; 99(2):178-84. PubMed ID: 9005985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPS induces eosinophil migration via CCR3 signaling through a mechanism independent of RANTES and Eotaxin.
    Penido C; Castro-Faria-Neto HC; Vieira-de-Abreu A; Figueiredo RT; Pelled A; Martins MA; Jose PJ; Williams TJ; Bozza PT
    Am J Respir Cell Mol Biol; 2001 Dec; 25(6):707-16. PubMed ID: 11726396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation stages of eosinophils characterized by hyaluronic acid binding via CD44 and responsiveness to stimuli.
    Watanabe Y; Hashizume M; Kataoka S; Hamaguchi E; Morimoto N; Tsuru S; Katoh S; Miyake K; Matsushima K; Tominaga M; Kurashige T; Fujimoto S; Kincade PW; Tominaga A
    DNA Cell Biol; 2001 Apr; 20(4):189-202. PubMed ID: 11403716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor.
    Suzuki K; Morokata T; Morihira K; Sato I; Takizawa S; Kaneko M; Takahashi K; Shimizu Y
    Eur J Pharmacol; 2007 Jun; 563(1-3):224-32. PubMed ID: 17336292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The carboxyl terminus of the chemokine receptor CCR3 contains distinct domains which regulate chemotactic signaling and receptor down-regulation in a ligand-dependent manner.
    Sabroe I; Jorritsma A; Stubbs VE; Xanthou G; Jopling LA; Ponath PD; Williams TJ; Murphy PM; Pease JE
    Eur J Immunol; 2005 Apr; 35(4):1301-10. PubMed ID: 15739168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.